TB-500

Thymosin β4 is a 43-amino-acid acidic peptide originally isolated from bovine thymus tissue and now recognized as one of the major intracellular G-actin sequestering proteins in mammalian cells. It binds monomeric actin (G-actin) and prevents its polymerization into F-actin, regulating cytoskeletal dynamics and cell motility. The cardiac-repair literature anchored by Bock-Marquette and colleagues (Nature 2004) extends the mechanism: thymosin β4 promotes myocardial and endothelial cell migration in embryonic hearts, retains that property in postnatal cardiomyocytes, and activates an integrin-linked kinase / Akt survival pathway that improves cardiac function after coronary artery ligation in mice ([Bock-Marquette et al., *Nature* 2004, 432:466–472](https://doi.org/10.1038/nature03000)). The peptide also induces angiogenesis, supports fibroblast migration, and has anti-inflammatory and antioxidant properties in dermal and corneal repair models. The market name "TB-500" is used interchangeably in research-peptide channels with thymosin β4, although some product literature historically describes TB-500 as a synthetic fragment containing the central actin-binding motif rather than the full 43-amino-acid peptide; the academic literature studies the full molecule.

TB-500 is the second healing-class peptide most biohackers reach for, almost always in a stack with BPC-157. The practitioner protocol — concurrent subcutaneous BPC-157 and TB-500, often near an injury site — has wide adoption and limited published controlled-trial support. The mechanistic case for use is genuinely strong on paper. Thymosin β4 has been studied across dermal wound healing in normal, diabetic, steroid-treated, and aged rodent models; in corneal epithelial defect models; in cardiac infarction repair (Bock-Marquette 2004 and follow-up work); and in clinical development for ischemic heart disease and neurotrophic keratopathy. RegeneRx's RGN-259 (a 0.1% thymosin β4 ophthalmic solution) progressed through Phase III trials for neurotrophic keratopathy, the most advanced clinical-development program of any healing-class peptide on this site. The bridge from that preclinical and ophthalmic-development evidence to "subcutaneous TB-500 for tendon and muscle repair" is mostly absent. There are no large randomized controlled trials of subcutaneous thymosin β4 for the musculoskeletal indications that drive recreational use; what exists is mechanistic plausibility from animal models and practitioner reports. The TB-500 + BPC-157 stack is the repair-class default by convention more than by direct evidence — the two peptides act on different mechanisms (BPC-157 on the VEGFR2-eNOS-NO axis and tendon fibroblast migration; thymosin β4 on actin sequestration and broader cell-migration regulation), and the rationale for combining them is mechanistic complementarity rather than head-to-head trial data. The honest reading: thymosin β4 is mechanistically one of the most interesting healing peptides in the literature, and one of the few with a real Phase III development program in a specific indication. The translation to systemic subcutaneous use for general repair is much less well-grounded than the practitioner consensus suggests, and the human safety record outside ophthalmic use is sparse.